Aclaris Therapeutics (ACRS) Total Liabilities: 2017-2025
Historic Total Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $55.4 million.
- Aclaris Therapeutics' Total Liabilities rose 6.11% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year increase of 6.11%. This contributed to the annual value of $64.8 million for FY2024, which is 61.02% up from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Total Liabilities is $55.4 million, which was down 3.44% from $57.4 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Total Liabilities ranged from a high of $64.8 million in Q4 2024 and a low of $27.2 million during Q2 2024.
- Over the past 3 years, Aclaris Therapeutics' median Total Liabilities value was $54.0 million (recorded in 2025), while the average stood at $50.4 million.
- In the last 5 years, Aclaris Therapeutics' Total Liabilities tumbled by 51.25% in 2024 and then soared by 110.68% in 2025.
- Aclaris Therapeutics' Total Liabilities (Quarterly) stood at $53.9 million in 2021, then climbed by 5.76% to $57.0 million in 2022, then fell by 29.40% to $40.2 million in 2023, then spiked by 61.02% to $64.8 million in 2024, then grew by 6.11% to $55.4 million in 2025.
- Its Total Liabilities was $55.4 million in Q3 2025, compared to $57.4 million in Q2 2025 and $54.0 million in Q1 2025.